Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prus...
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its propri...
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3027780/summary.html
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36)...
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr...
Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cel...
